You are using an older browser version. Please use a supported version for the best MSN experience.

Novavax becomes fifth COVID-19 vaccine developer to release promising early results

USA TODAY logo USA TODAY 8/5/2020 Karen Weintraub, USA TODAY
UP NEXT
UP NEXT

More good news in the pursuit of a COVID-19 vaccine: A fifth vaccine developer has released promising results from a small, early trial.

Novavax Inc., of Gaithersburg, Maryland, released the results via a news release and call with media late Tuesday, showing the vaccine appeared safe and elicited a similar immune response to an active infection with COVID-19.

"Good news," said Dr. William Schaffner, a professor and infectious disease expert at the Vanderbilt University School of Medicine in Nashville, Tennessee. "I think it clearly boosts confidence that we will have one or more vaccines."

Start the day smarter. Get all the news you need in your inbox each morning.

Moderna, AstraZeneca and Pfizer have all released promising Phase 1 results, with the first two publishing in major journals. Chinese researchers also have published early trial results, and have begun providing their candidate vaccine to members of the military, Reuters reported.

In the new trial, participants were divided into four groups of 25, company president Dr. Gregory Glenn said on the media call, sharing slides of the results. One group received a placebo. One group received one dose of the vaccine, called NVX‑CoV2373. A third group received two 5-microgram doses of the vaccine plus an adjuvant meant to boost the vaccine's strength. The last group received two higher doses, of 25 micrograms, plus the booster.

A nurse prepares a shot as a study of a possible COVID-19 vaccine on July 27, 2020, in Binghamton, New York. © Hans Pennink/AP A nurse prepares a shot as a study of a possible COVID-19 vaccine on July 27, 2020, in Binghamton, New York.

None of the trial participants had a severe reaction to the vaccine; most just had sore arms for a day or two. Reactions to the second dose of the vaccine were more significant than the first, which is typical.

The vaccine seems to have generated an immune reaction similar to those in people who have recovered from COVID-19, the data shows. True effectiveness cannot be determined until the vaccine candidate is tested in many more volunteers.

Novavax has received $1.6 billion from the federal government to complete development of NVX‑CoV2373 and to scale up manufacturing. The government will own 100 million doses of the developmental vaccine.

The company also has started production in six other countries, including in Europe, India and other parts of Asia, producing 1 billion to 2 billion doses next year, according to company CEO and president Stanley Erck. 

The company plans to publish the trial results in a peer reviewed journal, which is the standard for scientific publications. 

Schaffner said he thinks it was acceptable to release results via news release, because several of the other companies have done it, and "it has become the new normal." It would be "terrible for the company" if it came out later the information they released was shown to be inaccurate. 

The side effects seen in the study were very encouraging, Schaffner said, and a "small price to pay for protection against COVID-19."

Based on these results, he is confident that the U.S. Food and Drug Administration will support the company's move to shortly begin a Phase 2 trial in the U.S. and Australia, including older patients, and a large, Phase 3 trial by the end of September.

"Onward!" Schaffner said. 

Contact Karen Weintraub at kweintraub@usatoday.com

Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.

a close up of a clock: Experts estimate when a COVID-19 vaccine will be available to all Americans. © Javier Zarracina, USA TODAY Experts estimate when a COVID-19 vaccine will be available to all Americans.

This article originally appeared on USA TODAY: Novavax becomes fifth COVID-19 vaccine developer to release promising early results


Video: Novavax COVID-19 vaccine produces antibodies in small study (Reuters - US Video Online)

AdChoices
AdChoices

More From USA TODAY

image beaconimage beaconimage beacon